THTX - Theratechnologies - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

THTX is currently covered by 3 analysts with an average price target of $16.19. This is a potential upside of $13.57 (517.94%) from yesterday's end of day stock price of $2.62.

Theratechnologies's activity chart (see below) currently has 9 price targets and 12 ratings on display. The stock rating distribution of THTX is 40% HOLD and 60% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 6.67% with an average time for these price targets to be met of 50.33 days.

Highest price target for THTX is $3, Lowest price target is $1, average price target is $10.

Most recent stock forecast was given by JOHN WALSH from on 17-Jul-2023. First documented stock forecast 01-Dec-2019.

Best performing analysts who are covering THTX - Theratechnologies:

Edward Nash Louise Chen John Walsh

Currently out of the existing stock ratings of THTX, 2 are a HOLD (40%), 3 are a BUY (60%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$12

$10.48 (689.47%)

$24

1 years 9 months 24 days ago
(17-Jul-2023)

0/2 (0%)

$8.68 (261.45%)

Buy

1 years 9 months 28 days ago
(13-Jul-2023)

0/1 (0%)

$27.52 (324.53%)

Hold

$8

$5.38 (205.34%)

$8

1 years 10 months 9 days ago
(02-Jul-2023)

1/5 (20%)

$4.52 (129.89%)

151

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is THTX (Theratechnologies) average time for price targets to be met?

On average it took 50.33 days on average for the stock forecasts to be realized with a an average price target met ratio 6.67

Which analyst has the current highest performing score on THTX (Theratechnologies) with a proven track record?

EDWARD NASH

Which analyst has the current lower performing score on THTX (Theratechnologies) with a proven track record?

JOHN WALSH

Which analyst has the most public recommendations on THTX (Theratechnologies)?

Edward Nash works at CANACCORD and has 5 price targets and 5 ratings on THTX

Which analyst is the currently most bullish on THTX (Theratechnologies)?

John Walsh with highest potential upside - $10.48

Which analyst is the currently most reserved on THTX (Theratechnologies)?

Louise Chen with lowest potential downside - -$0

Theratechnologies in the News

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of...

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV®sBLA Latest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular risk MONTREAL, April 09, 2025 (GLOBE NEWSWIRE)...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?